168 related articles for article (PubMed ID: 3285914)
1. A multicentre study on intensive induction and consolidation therapy in acute myelogenous leukaemia.
Kurrle E; Ehninger G; Freund M; Heil G; Hoelzer D; Link H; Mitrou PS; Ohl S; Queisser W; Schlimok G
Blut; 1988 May; 56(5):233-6. PubMed ID: 3285914
[No Abstract] [Full Text] [Related]
2. Intensive induction and consolidation chemotherapy for adults and children with acute myeloid leukaemia (AML) joint AML trial 1982-1985.
Marcus RE; Catovsky D; Prentice HG; Newland AC; Chessells JM; Stevens RF; Hann IM; Goldman JM; Hoffbrand AV; Galton DA
Haematol Blood Transfus; 1987; 30():346-51. PubMed ID: 2442074
[No Abstract] [Full Text] [Related]
3. Double intensive consolidation chemotherapy (ICC) for acute myeloid leukemia.
Harousseau JL; Milpied N; Briere J; Desablens B; Le Prise PY; Ifrah N; Gandhour C; Casassus P
Haematol Blood Transfus; 1990; 33():299-303. PubMed ID: 2323633
[No Abstract] [Full Text] [Related]
4. Intensive induction therapy with behenoyl, cytosine arabinoside, daunorubicin, and 6-mercaptopurine followed by intensive consolidation with mitoxantrone, etoposide, vincristine, and intermediate-dose continuous cytarabine (M-85 protocol) for adult acute myelogenous leukemia.
Ohno R; Yokomaku S; Okumara M; Tanimoto M; Morishita Y; Morishima Y; Kodera Y; Saito H
Haematol Blood Transfus; 1990; 33():304-8. PubMed ID: 2182424
[No Abstract] [Full Text] [Related]
5. Therapy of acute myelogenous leukemia in adults.
Petti MC; Broccia G; Caronia F; Di Raimondo F; Fioritoni G; Ladogana S; Leone G; Liso V; Musso M; Neri A
Haematol Blood Transfus; 1990; 33():249-53. PubMed ID: 2182417
[No Abstract] [Full Text] [Related]
6. Post-remission intensive consolidation with high-dose cytarabine-based chemotherapy and granulocyte colony-stimulatory factor in adults with acute myelogenous leukemia: a preliminary report.
Hsu HC; Chiu CF; Tan TD; Chau WK; Tseng CS; Ho CH
Zhonghua Yi Xue Za Zhi (Taipei); 1995 Nov; 56(5):305-11. PubMed ID: 8605644
[TBL] [Abstract][Full Text] [Related]
7. Remission induction and postremission therapy in acute myelogenous leukemia: British MRC Study.
Rees JK; Gray RG
Haematol Blood Transfus; 1990; 33():243-8. PubMed ID: 1691131
[No Abstract] [Full Text] [Related]
8. Etoposide in remission induction of adult acute myeloid leukemia.
Leoni F; Ciolli S; Patriarchi S; Morfini M; Rossi Ferrini P
Acta Haematol; 1990; 83(2):82-5. PubMed ID: 2106200
[TBL] [Abstract][Full Text] [Related]
9. Aclacinomycin-A in the induction treatment of childhood acute myelogenous leukemia.
Fink FM; Grümayer ER; Kardos G; Revesz T; Gadner H; Schuler D
Haematol Blood Transfus; 1987; 30():393-8. PubMed ID: 3305209
[No Abstract] [Full Text] [Related]
10. Acute myeloid leukemia in Manitoba. The consequences of standard "7 + 3" remission-induction therapy followed by high dose cytarabine postremission consolidation for myelosuppression, infectious morbidity, and outcome.
Bow EJ; Kilpatrick MG; Scott BA; Clinch JJ; Cheang MS
Cancer; 1994 Jul; 74(1):52-60. PubMed ID: 8004583
[TBL] [Abstract][Full Text] [Related]
11. Survival in 91 adults with acute myelogenous leukaemia treated with 1-6 intensive courses of chemotherapy.
Evensen SA; Brinch L; Stavem P; Tjønnfjord G
J Intern Med; 1992 Nov; 232(5):433-7. PubMed ID: 1453128
[TBL] [Abstract][Full Text] [Related]
12. A comparison of cytokinetically based versus intensive chemotherapy for childhood acute myelogenous leukemia.
Dahl GV; Kalwinsky DK; Mirro J; Look AT
Haematol Blood Transfus; 1987; 30():83-7. PubMed ID: 3305227
[No Abstract] [Full Text] [Related]
13. Prolonged survival in acute myelogenous leukaemia without maintenance chemotherapy.
Champlin R; Jacobs A; Gale RP; Boccia R; Elashoff R; Foon K; Zighelboim J
Lancet; 1984 Apr; 1(8382):894-6. PubMed ID: 6200742
[TBL] [Abstract][Full Text] [Related]
14. Consolidation therapy with high-dose cytosine arabinoside: experiences of a prospective study in acute myeloid leukemia.
Kurrle E; Ehninger G; Fackler-Schwalbe E; Freund M; Heil G; Hoelzer D; Link H; Löffler B; Lösch A; Mitrou PS
Haematol Blood Transfus; 1990; 33():254-60. PubMed ID: 2182418
[No Abstract] [Full Text] [Related]
15. The ninth British Medical Research Council trial for the treatment of acute myeloid leukaemia.
Rees JK; Gray R; Hayhoe FG
Haematol Blood Transfus; 1987; 30():35-7. PubMed ID: 2442075
[No Abstract] [Full Text] [Related]
16. Failure of lithium to limit neutropenia significantly during induction therapy of acute myelogenous leukemia. A Southeastern Cancer Study Group study.
Stein RS; Vogler WR; Lefante J
Am J Clin Oncol; 1984 Aug; 7(4):365-9. PubMed ID: 6430063
[TBL] [Abstract][Full Text] [Related]
17. A randomized study of intermediate versus conventional-dose cytarabine as intensive induction for acute myelogenous leukaemia.
Schiller G; Gajewski J; Nimer S; Territo M; Ho W; Lee M; Champlin R
Br J Haematol; 1992 Jun; 81(2):170-7. PubMed ID: 1643014
[TBL] [Abstract][Full Text] [Related]
18. [A short duration treatment with intensive consolidation therapy for patients with acute myelogenous leukemia--13 year experience in a single institute].
Fujiwara M; Satou N; Izumi N; Shibasaki Y; Higashimura M; Tsukada N; Koike T
Gan To Kagaku Ryoho; 2007 Nov; 34(11):1793-8. PubMed ID: 18030012
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic versus autologous bone marrow transplantation (BMT) versus intensive consolidation in acute myelogenous leukemia (AML) in first remission. An EORTC-Gimema phase III trial (AML8 A). The EORTC Leukemia Cooperative Group and the GIMEMA Group.
Zittoun R; Mandelli F; Willemze R; de Witte T; Tura S; Ferrini PR; Stryckmans P; Gattringer C; Petti MC; Solbu G
Leukemia; 1992; 6 Suppl 2():114-5. PubMed ID: 1578909
[No Abstract] [Full Text] [Related]
20. A phase-three trial comparing daunorubicin or idarubicin combined with cytosine arabinoside in acute myelogenous leukemia.
Vogler WR; Velez-Garcia E; Omura G; Raney M
Semin Oncol; 1989 Feb; 16(1 Suppl 2):21-4. PubMed ID: 2648581
[No Abstract] [Full Text] [Related]
[Next] [New Search]
